| Topic: |
Hematologic Diseases (HE) |
| Title: |
Revlimid Approved by the FDA. |
| Author: |
n/a |
| Source: |
Aplastic Anemia and MDS International Foundation, Inc. 19(1): 1. Winter 2006. |
| Availability: |
Available from Aplastic Anemia and MDS International Foundation, Inc. PO Box 613, Annapolis, MD 21404. Phone: 1-800-747-2820. Email: help@aamds.org. Website: www.aamds.org. Price: Available free of charge on website. |
| Abstract: |
This brief newsletter article reports on the recent approval by the U.S. Food and Drug Administration (FDA) of the drug lenolidomide (Revlimid) for the treatment of patients with a subgroup of myelodysplastic syndromes (MDS). This oral medication is approved for the treatment of low- or intermediate-risk MDS associated with deletion of 5q, a chromosomal abnormality. Lenolidomide is an immunomodulatory drug, chemically similar to thalidomide. The article notes that because of concerns about severe birth defects occurring in any women who may become pregnant while on lenolidomide, or whose male partners may be taking lenolidomide, the drug is being marketed and supported by a special risk management program called RevAssist (www.revlimid.com or 800-747-2820). |
| Format: |
Newsletter Article |
| Language: |
English. |
| Major Keywords: |
Hematologic Diseases. Myelodysplastic Syndromes. Drug Therapy. Drug Effects. |
| Minor Keywords: |
Pharmaceutical Industry. Patient Education. Immune System. Congenital Anomalies. Risk Factors. |
| Publication Number: |
HEJA10011. |
| Printer-Friendly Version | Return to Search Results |
|
<-- previous record
|
next record -->
|
